Sentiment-Signal
21,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Unternehmen & Branche
| Name | Enliven Therapeutics, Inc. |
|---|---|
| Ticker | ELVN |
| CIK | 0001672619 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,56 Mrd. USD |
| Beta | 0,49 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -103,694,000 | -1.83 | 476,168,000 | 459,600,000 | |
| 2025-09-30 | 10-Q | -20,148,000 | -0.32 | 490,875,000 | 476,122,000 | |
| 2025-06-30 | 10-Q | -25,335,000 | -0.49 | 503,887,000 | 488,472,000 | |
| 2025-03-31 | 10-Q | -28,544,000 | -0.57 | 302,570,000 | 288,296,000 | |
| 2024-12-31 | 10-K | -89,024,000 | -1.89 | 325,760,000 | 309,845,000 | |
| 2024-09-30 | 10-Q | -23,156,000 | -0.48 | 305,430,000 | 288,403,000 | |
| 2024-06-30 | 10-Q | -19,950,000 | -0.41 | 327,043,000 | 304,932,000 | |
| 2024-03-31 | 10-Q | -22,738,000 | -0.54 | 342,777,000 | 317,712,000 | |
| 2023-12-31 | 10-K | -71,584,000 | -2.01 | 271,867,000 | 245,906,000 | |
| 2023-09-30 | 10-Q | -20,769,000 | -0.51 | 274,041,000 | 261,748,000 | |
| 2023-06-30 | 10-Q | -16,721,000 | -0.41 | 288,501,000 | 278,994,000 | |
| 2023-03-31 | 10-Q | -14,724,000 | -0.80 | 302,866,000 | 291,416,000 | |
| 2022-12-31 | 10-K | -37,662,000 | -12.05 | 83,298,000 | -76,825,000 | |
| 2022-09-30 | 10-Q | -10,554,000 | -3.27 | 59,104,000 | -68,097,000 | |
| 2022-06-30 | 10-Q | -8,889,000 | -2.86 | 64,666,000 | -58,713,000 | |
| 2022-03-31 | 10-Q | -8,669,000 | -3.01 | 81,602,000 | -50,610,000 | |
| 2021-12-31 | 10-K | -51,384,000 | -2.37 | 93,646,000 | -42,887,000 | |
| 2021-09-30 | 10-Q | -13,647,000 | -0.74 | 107,027,000 | 99,373,000 | |
| 2021-06-30 | 10-Q | -13,161,000 | -0.74 | 72,468,000 | 64,967,000 | |
| 2021-03-31 | 10-Q | -10,257,000 | 81,687,000 | 75,594,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -140 | 45.81 | -6,413.50 | -2,5% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,441 | 48.06 | -117,303.48 | -45,4% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,419 | 47.39 | -114,635.44 | -44,4% | |
| 2026-03-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,000 | 27.76 | -138,800.00 | -53,8% | |
| 2026-03-10 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10,129 | 30.19 | -305,826.92 | -118,4% | |
| 2026-03-09 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29,871 | 30.02 | -896,811.06 | -347,3% | |
| 2026-03-06 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -10,000 | 29.58 | -295,839.00 | -114,6% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1,230 | 26.18 | -32,196.36 | -12,5% | |
| 2026-02-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -45,000 | 26.17 | -1,177,861.50 | -456,2% | |
| 2026-02-06 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,000 | 29.04 | -145,219.00 | -56,2% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -14,509 | 26.90 | -390,284.85 | -151,2% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26.96 | -19,354.41 | -7,5% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26.46 | -13,547.11 | -5,2% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,491 | 26.37 | -144,814.14 | -56,1% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -50,000 | 29.13 | -1,456,715.00 | -564,2% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -48,057 | 27.98 | -1,344,836.70 | -520,8% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -243 | 28.50 | -6,925.50 | -2,7% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4,285 | 25.00 | -107,125.43 | -41,5% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -41,198 | 24.90 | -1,025,863.16 | -397,3% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -33,802 | 24.92 | -842,474.29 | -326,3% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7,500 | 20.13 | -150,961.50 | -58,5% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1,620 | 25.00 | -40,500.00 | -15,7% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8,015 | 25.04 | -200,655.53 | -77,7% | |
| 2025-12-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,000 | 16.84 | -84,206.00 | -32,6% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4,958 | 20.76 | -102,938.99 | -39,9% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1,705 | 21.78 | -37,133.88 | -14,4% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -492 | 23.09 | -11,360.77 | -4,4% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12,008 | 22.30 | -267,794.01 | -103,7% | |
| 2025-11-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12,500 | 21.82 | -272,738.75 | -105,6% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6,054 | 17.35 | -105,038.72 | -40,7% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -613 | 17.94 | -10,995.44 | -4,3% | |
| 2025-10-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12,500 | 22.08 | -276,025.00 | -106,9% | |
| 2025-10-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12,500 | 21.33 | -266,653.75 | -103,3% | |
| 2025-10-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6,667 | 20.10 | -133,992.70 | -51,9% | |
| 2025-09-29 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3,250 | 20.40 | -66,291.23 | -25,7% | |
| 2025-09-26 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -3,700 | 20.06 | -74,227.55 | -28,7% | |
| 2025-09-26 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4,000 | 20.25 | -81,005.20 | -31,4% | |
| 2025-09-23 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -2,800 | 20.03 | -56,084.00 | -21,7% | |
| 2025-09-23 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -1,500 | 20.03 | -30,045.00 | -11,6% | |
| 2025-09-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1,000 | 20.25 | -20,250.00 | -7,8% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4,870 | 19.11 | -93,063.27 | -36,0% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -2,130 | 20.02 | -42,634.08 | -16,5% | |
| 2025-09-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -5,000 | 19.09 | -95,473.00 | -37,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.